Compare MARPS & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MARPS | PHIO |
|---|---|---|
| Founded | 1956 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 11.2M |
| IPO Year | N/A | 2011 |
| Metric | MARPS | PHIO |
|---|---|---|
| Price | $4.95 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 6.3K | ★ 126.0K |
| Earning Date | 02-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.05 | $0.81 |
| 52 Week High | $6.49 | $4.19 |
| Indicator | MARPS | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.55 | 49.14 |
| Support Level | $4.74 | $1.00 |
| Resistance Level | $5.20 | $1.14 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 73.88 | 69.24 |
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.